2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Outstanding mix of clinical abstracts, including clinical trials, retrospective analysis, and molecular observations in myelofibrosis, polycythemia vera, essential thrombocythemia and other myeloid neoplasms
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2052 A novel tool to predict thrombosis in myelofibrosis patients treated with ruxolitinib: The R-NAT score

Francesca Palandri, MD, PhD, Alessandro Laganà, MD2, Massimiliano Bonifacio, MD3, Elena Maria Elli4, Elisabetta Abruzzese, MD, PhD5, Mario Tiribelli, MD6, Erika Morsia, MD7, Mirko Farina, MD, PhD8, Giulia Benevolo, MD9, Novella Pugliese, MD, PhD10, Alessia Tieghi, MD11, Gianni Binotto12, Francesco Cavazzini, MD13, Monica Crugnola, MD14, Andrea Duminuco, MD15, Olga Mulas16, Alessandra Dedola17, Fabrizio Cavalca, MD18, Bruno Martino19, Daniela Cilloni, MD20, Monica Bocchia21, Giovanni Caocci, MD22, Florian H. Heidel IV, MD23, Giuseppe Palumbo24, Chiara Sartor, MD25, Massimo Breccia, MD26, Filippo Branzanti27
1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
2 Az. Policlinico Umberto I-Sapienza University, Rome, Italy
3 University of Verona, Verona, Italy
4 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
5 Ospedale S. Eugenio, Rome, Italy
6 University of Udine, Udine, Italy
7 Università Politecnica delle Marche, Ancona, Italy
8 ASST Spedali Civili of Brescia, Brescia, Italy
9 Citta` della Salute e della Scienza Hospital, Torino, Italy
10 Federico II University Medical School, Naples, Italy
11 Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy
12 University of Padova, Padova, Italy
13 University of Ferrara, Ferrara, Italy
14 Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
15 AOU Policlinico “G. Rodolico” – San Marco, Catania, Italy
16 Ospedale Businco, Università degli studi di Cagliari, Cagliari, Italy
17 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Università di Bologna, Bologna, Italy
18 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
19 Azienda Ospedaliera 'Bianchi Melacrino Morelli', Reggio Calabria, Italy
20 University of Turin, Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Italy
21 University of Siena, Siena, Italy
22 Ospedale Businco, Università degli studi di Cagliari, Cagliari, Italy
23 Hannover Medical School (MHH), Hannover, Germany
24 University of Catania, Catania, Italy
25 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
26 Az. Policlinico Umberto I-Sapienza University, Rome, Italy
27 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Background

Thrombotic events remain major complications in myelofibrosis (MF), but MF‑specific prognostic models are lacking. As a result, thrombotic risk scores developed for polycythemia vera (PV) and essential thrombocythemia (ET) are sometimes applied to MF, although their performance, particularly in patients (pts) receiving ruxolitinib (RUX), a JAK1/2 inhibitor with anti‑inflammatory and anti‑thrombotic properties, remains unclear.

The neutrophil‑to‑lymphocyte ratio (NLR), a simple inflammatory marker, has shown prognostic relevance in PV, ET and early primary MF (PMF).

We aimed to: 1) evaluate the performance of existing PV/ET-derived thrombotic risk models in RUX-treated MF pts; 2) assess the role of baseline and early-treatment NLR as a thrombosis predictor; 3) develop and validate a novel MF-specific thrombotic risk score, tailored to MF pts receiving RUX.

Methods

A derivation cohort of 1150 RUX-treated MF pts (NCT0651406) and an external validation cohort from Sapienza University (n=248) were analyzed. Thrombotic risk was classified using: 1) IPSET-T [based on age, cardiovascular risk factors (CVRF), prior thrombosis, and JAK2 mutation]; 2) binary thrombotic risk model (low risk: age <60 years and no prior thrombosis; high risk: ≥1 risk factor). Baseline NLR ≤3.53 was considered normal according to Forget et al, BMC Res Notes 10, 12 (2017). Multivariable (MVA) Cox models identified independent predictors and were used to develop an MF-specific thrombotic score, which underwent internal and external validation.

Results

At RUX start in the derivation cohort 78.1% of pts were >60 yrs old, 61.0% had ≥1 CVRF, 75.2% harbored JAK2 mutation (mean VAF: 54.7%), and 16.2% had prior thrombosis. Mean baseline NLR (n=1126) was 7.4. JAK2 VAF >50% (52.1%) and NLR >3.53 (70.6%) showed significant collinearity (r=0.71, Variance Inflation Factor=7.12). Based on IPSET‑T (n=754), 13.9%, 16.2% and 69.9% were low, intermediate and high risk. By conventional criteria, 17.7% were low risk.

During RUX treatment, 85 thrombosis occurred in 78 pts (6.8%), yielding an incidence rate (IR) of 2.19x100 patient‑years (%py). Venous events predominated (1.57 vs 0.62%py arterial). 5-yr Thrombosis Free Survival (TFS) was 89.6%.

Thrombotic IRs were similar across IPSET‑T categories (2.48 vs 1.81 vs 2.70 in low, intermediate and high-risk pts, respectively). Binary stratification effectively discriminated thrombotic risk (0.87 vs 2.69%py in low vs high-risk, p=0.004). NLR >3.53 increased thrombotic risk (HR 1.91, p=0.04).

In a 3‑month landmark analysis, 59 (25.5%) out of 231 evaluable pts with baseline NLR ≤3.53 increased to >3.53. An NLR rise was associated with a higher subsequent thrombotic risk (HR 4.21 for increased vs. stable‑low, p=0.049). Among the 451 pts with high baseline NLR, 175 (38.8%) decreased to ≤3.53, corresponding to a lower thrombotic risk (HR 2.63 for stable‑high vs decreased, p=0.015).

In MVA, baseline age >60 (HR 2.99, p=0.004), prior thrombosis (HR 1.93, p=0.010), and NLR >3.53 (HR 1.86, p=0.048) were identified as independent predictors of thrombosis.

Based on these variables, we developed a three-factor R-NAT (Ruxolitinib-NLR, Age, Thrombosis) Score assigning 2 points to age >60 yrs and 1 point each to prior thrombosis and NLR >3.53 (range, 0–4). Pts were stratified into low (points 0–1, reference), intermediate (2–3; HR 2.85, p=0.015) and high risk (4; HR 6.55, p<0.001) groups, with 5-yr TFS of 96.6%, 88.5%, and 79.7%, respectively. The corresponding thrombotic IR were 0.82, 2.34 and 4.77%py (p<0.0001). The new score outperformed IPSET-T and binary classification (C-index 0.64 vs 0.53 vs 0.56).

Internal validation using 1000 bootstrap resamples confirmed the robustness of its discriminative performance (observed log-rank χ²=19.3; bootstrap p=0.044).

The score was successfully validated in the independent Sapienza cohort, including 248 pts with comparable baseline characteristics and showing an overall thrombotic IR of 1.76%py. The R-NAT confirmed its ability to effectively stratify thrombotic risk (5-yr TFS: 95.9%, 87.3% and 74.5%, respectively) with satisfactory prognostic performance (C-index 0.68).

Conclusions

Inflammatory status, as reflected by NLR, plays a major role in thrombotic vulnerability during RUX. The R-NAT Score provides MF‑specific risk stratification superior to existing models. Baseline and early‑treatment NLR emerge as accessible biomarkers linking inflammatory control to thrombotic risk.

Francesca Palandri, MD, PhD: GlaxoSmithKline - Honoraria; Novartis - Honoraria; Amgen - Honoraria; Grifols - Honoraria; Incyte - Honoraria; Bristol Myers Squibb - Honoraria; AOP Health - Honoraria; Takeda - Honoraria; Sobi - Honoraria; Sanofi - Honoraria; GlaxoSmithKline - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Grifols - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); AOP Health - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony)